Clinical Trial: A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Enhancing Brain Lesions After Radiation Therapy: A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression

Brief Summary:

This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the tumor cells are actively growing. The investigators will do these two tests and see which one is better.

Optional Second MRI Perfusion

The investigators may ask the patient to undergo a second MRI perfusion scan. They are testing this second scan to see how well it works. It can cover the entire brain. It takes about an 5 extra minutes in the scanner. If they decide to undergo this second scan, they will divide the usual IV contrast dose into two parts. The patient will not receive extra IV contrast for this second scan. This second scan is optional.


Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center

Current Primary Outcome: imaging techniques [ Time Frame: 2 years ]

To assess the utility of PET/CT and MRI perfusion studies in predicting whether worsening enhancing brain lesions seen after radiation therapy represent radiation injury or tumor progression. This study will examine the role of these two imaging techniques in predicting diagnosis and treatment planning.


Original Primary Outcome: Same as current

Current Secondary Outcome: predicting tumor progression [ Time Frame: 2 years ]

To assess the utility of PET and MRI perfusion studies in predicting tumor progression in patients with tumors with a history of brain radiation therapy receiving anti-angiogenic therapy (such as bevacizumab).


Original Secondary Outcome: predicting tumor progression [ Time Frame: 2 years ]

To assess the utility of PET and MRI perfusion studies in predicting tumor progression in patients with malignant gliomas and brain metastases receiving anti-angiogenic therapy (such as bevacizumab).


Information By: Memorial Sloan Kettering Cancer Center

Dates:
Date Received: May 21, 2012
Date Started: May 2012
Date Completion: May 2018
Last Updated: December 19, 2016
Last Verified: December 2016